An Overview of PARP Inhibitors for the Treatment of Breast Cancer

Loss-of-function mutations in BRCA1 and BRCA2 are detected in at least 5% of unselected patients with breast cancer (BC). These BC susceptibility genes encode proteins critical for DNA homologous recombination repair (HRR). This review provides an update on oral poly(ADP-ribose) polymerase (PARP) in...

Descripción completa

Detalles Bibliográficos
Autores principales: Cortesi, Laura, Rugo, Hope S., Jackisch, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8105250/
https://www.ncbi.nlm.nih.gov/pubmed/33710534
http://dx.doi.org/10.1007/s11523-021-00796-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8105250/
https://www.ncbi.nlm.nih.gov/pubmed/33710534
http://dx.doi.org/10.1007/s11523-021-00796-4

Ejemplares similares